• 

  Hetero launches pack of generic coronavirus drug favipiravir at Rs 2,640

  Business | September 25, 2020 18:57 IST

  Favivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at Rs 2,640 per pack, Hetero said in a statement.

• 

  Hetero launches generic COVID-19 drug at Rs 59 per table

  Business | July 29, 2020 13:00 IST

  Favivir improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms.

• 

  Hetero Healthcare Ltd starts supply of generic Remdesivir

  Business | July 15, 2020 12:53 IST

  Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease.

• 

  Hetero set to deliver 20,000 vials of generic Remdesivir

  Business | June 24, 2020 16:16 IST

  Following the approval of Covifor, the generic version of Remdesivir, by the Drug Controller General of India (DCGI), Hetero Healthcare Limited is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each. 

• 

  Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts

  India | June 22, 2020 23:06 IST

  With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

• 

  Hetero gets DCGI nod to launch COVID-19 drug

  Business | June 21, 2020 15:07 IST

  Drug firm Hetero on Sunday said it has received approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the treatment of COVID-19.

• 

  Swine flu: Hetero Healthcare increases anti-H1N1 drug Fluvir production by 400%

  India | February 26, 2015 19:34 IST

  Hyderabad: City-based Hetero Healthcare Limited, the first pharma company in India to launch anti-H1N1 drug Oseltamivir in retail market, today said it has increased its Fluvir production by 400 per cent to address the present